The China NMPA’s Center for Drug Evaluation accepted Lepu Biopharma Co. Ltd.’s new drug application (NDA) for anti-PD-1 antibody candidate HX-008 (pucotenlimab). That comes after the company filed for an IPO in Hong Kong.
Innovent Biologics Inc. and Ascentage Pharma Group Corp. Ltd. inked a three-component collaboration that comes with joint commercialization of an NDA-stage Bcr-Abl inhibitor and co-development of combination therapies, as well as Innovent taking a stake in Ascentage. The collaboration involves a deal worth up to $145 million and a $50 million investment.
Harbour Biomed Therapeutics Ltd. said its anti-FcRn monoclonal antibody, batoclimab, generated top-line phase II data in generalized myasthenia gravis, and the company expects to move into a phase III study by the end of this year, with final data reported in April 2022.
The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study showed that one of those vaccines, Sinovac Biotech Ltd.’s Coronavac, was less effective than Pfizer Inc. and Biontech SE’s Comirnaty in Chile.
Keymed Biosciences Inc. debuted on the Hong Kong Stock Exchange (HKSE) on July 8, raising HK$2.94 billion (US$378.48 million) in the process. The company will use the funds raised for the R&D and commercialization of key pipeline candidates.
I-Mab Biopharma Co. Ltd. announced collaborations with mRNA biotech company Immorna (Hangzhou) Biotechnology Co. Ltd. and AI-enabled R&D company Neox Biotech Co. Ltd., gaining access to transformative technologies to discover and develop oncology therapeutics.
Fresh from showcasing preliminary evidence for the tolerability and potential benefits of LVGN-6051 at ASCO’s annual meeting in June, Lyvgen Biopharma Holdings Co. Ltd. is gearing up to move its CD40 agonist LVGN-7409 to clinical trials in China after initial U.S. patient dosing.
I-Mab Biopharma Co. Ltd. announced collaborations with mRNA biotech company Immorna (Hangzhou) Biotechnology Co. Ltd. and AI-enabled R&D company Neox Biotech Co. Ltd., gaining access to transformative technologies to discover and develop oncology therapeutics.
Fresh from showcasing preliminary evidence for the tolerability and potential benefits of its anti-CD137 monoclonal antibody, LVGN-6051, at the American Society of Clinical Oncology’s annual meeting in June, Lyvgen Biopharma Holdings Co. Ltd. is gearing up to move its CD40 agonist LVGN-7409 to clinical trials in China after initial U.S. patient dosing.
Neuro- and peripheral-vascular interventional med-tech developer Zylox-Tonbridge Medical Technology Co. Ltd. raised HK$2.56 billion (US$329 million) in Hong Kong on July 5 via an IPO that will support the development and commercialization of its core products.
RSS
